Literature DB >> 10364318

Inhibition of herpes simplex virus gD and lymphotoxin-alpha binding to HveA by peptide antagonists.

M R Sarrias1, J C Whitbeck, I Rooney, L Spruce, B K Kay, R I Montgomery, P G Spear, C F Ware, R J Eisenberg, G H Cohen, J D Lambris.   

Abstract

The herpesvirus entry mediator A (HveA) is a recently characterized member of the tumor necrosis factor receptor family that mediates the entry of most herpes simplex virus type 1 (HSV-1) strains into mammalian cells. Studies on the interaction of HSV-1 with HveA have shown that of all the viral proteins involved in uptake, only gD has been shown to bind directly to HveA, and this binding mediates viral entry into cells. In addition to gD binding to HveA, the latter has been shown to interact with proteins of tumor necrosis factor receptor-associated factor family, lymphotoxin-alpha (LT-alpha), and a membrane-associated protein referred to as LIGHT. To study the relationship between HveA, its natural ligands, and the viral proteins involved in HSV entry into cells, we have screened two phage-displayed combinatorial peptide libraries for peptide ligands of a recombinant form of HveA. Affinity selection experiments yielded two peptide ligands, BP-1 and BP-2, which could block the interaction between gD and HveA. Of the two peptides, only BP-2 inhibited HSV entry into CHO cells transfected with an HveA-expressing plasmid. When we analyzed these peptides for the ability to interfere with HveA binding to its natural ligand LT-alpha, we found that BP-1 inhibited the interaction of cellular LT-alpha with HveA. Thus, we have dissected the sites of interaction between the cell receptor, its natural ligand LT-alpha and gD, the virus-specific protein involved in HSV entry into cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10364318      PMCID: PMC112627     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry.

Authors:  J C Whitbeck; C Peng; H Lou; R Xu; S H Willis; M Ponce de Leon; T Peng; A V Nicola; R I Montgomery; M S Warner; A M Soulika; L A Spruce; W T Moore; J D Lambris; P G Spear; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 2.  Laser desorption mass spectrometry.

Authors:  W T Moore
Journal:  Methods Enzymol       Date:  1997       Impact factor: 1.600

3.  Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family.

Authors:  R I Montgomery; M S Warner; B J Lum; P G Spear
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

4.  The lymphotoxin-alpha (LTalpha) subunit is essential for the assembly, but not for the receptor specificity, of the membrane-anchored LTalpha1beta2 heterotrimeric ligand.

Authors:  L Williams-Abbott; B N Walter; T C Cheung; C R Goh; A G Porter; C F Ware
Journal:  J Biol Chem       Date:  1997-08-01       Impact factor: 5.157

5.  Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1.

Authors:  S A Marsters; T M Ayres; M Skubatch; C L Gray; M Rothe; A Ashkenazi
Journal:  J Biol Chem       Date:  1997-05-30       Impact factor: 5.157

6.  Antigenic structure of soluble herpes simplex virus (HSV) glycoprotein D correlates with inhibition of HSV infection.

Authors:  A V Nicola; C Peng; H Lou; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

7.  ATAR, a novel tumor necrosis factor receptor family member, signals through TRAF2 and TRAF5.

Authors:  H Hsu; I Solovyev; A Colombero; R Elliott; M Kelley; W J Boyle
Journal:  J Biol Chem       Date:  1997-05-23       Impact factor: 5.157

8.  Herpesvirus entry mediator HVEM mediates cell-cell spread in BHK(TK-) cell clones.

Authors:  R J Roller; D Rauch
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

9.  Structure-function analysis of soluble forms of herpes simplex virus glycoprotein D.

Authors:  A V Nicola; S H Willis; N N Naidoo; R J Eisenberg; G H Cohen
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Identification of calmodulin-binding peptide consensus sequences from a phage-displayed random peptide library.

Authors:  N B Adey; B K Kay
Journal:  Gene       Date:  1996-02-22       Impact factor: 3.688

View more
  5 in total

1.  Structure-based analysis of the herpes simplex virus glycoprotein D binding site present on herpesvirus entry mediator HveA (HVEM).

Authors:  Sarah A Connolly; Daniel J Landsburg; Andrea Carfi; Don C Wiley; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway.

Authors:  Timothy C Cheung; Ian R Humphreys; Karen G Potter; Paula S Norris; Heather M Shumway; Bonnie R Tran; Ginelle Patterson; Rochelle Jean-Jacques; Miri Yoon; Patricia G Spear; Kenneth M Murphy; Nell S Lurain; Chris A Benedict; Carl F Ware
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-30       Impact factor: 11.205

3.  A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.

Authors:  Lino C Gonzalez; Kelly M Loyet; Jill Calemine-Fenaux; Vandana Chauhan; Bernd Wranik; Wenjun Ouyang; Dan L Eaton
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-12       Impact factor: 11.205

Review 4.  Compstatin: a complement inhibitor on its way to clinical application.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

Review 5.  Recent progress in herpes simplex virus immunobiology and vaccine research.

Authors:  David M Koelle; Lawrence Corey
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.